Integer Announces Appointment of Joseph W. Dziedzic as President and Chief Executive Officer

Published on:

FRISCO, Texas, July 17, 2017 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR), a leading medical device outsource (MDO) manufacturer, today announced that Joseph W. Dziedzic has been appointed by Integer’s Board of Directors to serve as President & Chief Executive Officer, removing his interim designation. Mr. Dziedzic has entered into a new three-year Employment Agreement with the Company effective today.

Mr. Dziedzic has served as Integer’s Interim President & CEO since March 2017 and as a director of the Company since February 2013. Previously he was Executive Vice President and Chief Financial Officer for The Brink’s Company from 2009 to 2016. Prior to that, he had a 20-year career with General Electric, in which he held leadership roles in six businesses, including General Electric Medical Systems.

Bill R. Sanford, Integer Chairman of the Board, commented, “After conducting a comprehensive search for a permanent President & CEO, the choice was clear. Joe’s deep understanding of our business, stemming from his service on the Board since 2013, coupled with his prior executive experience and the skillful leadership he demonstrated during his service as our Interim CEO, have shown him to be an ideal fit. The Board is confident Joe is the right person to lead Integer to realize our vision of enhancing the lives of patients worldwide by being our customers’ partner of choice for innovative medical technologies and services.”

“This is an exciting time for Integer,” Mr. Dziedzic stated. “As the market leader in MDO manufacturing, we have unrivaled capabilities to serve our customers’ needs across the full range of our product continuum, from medical device components to full-system solutions and devices. During my time as Interim CEO, I observed first-hand the talent, expertise and dedication of the Integer team, making me even more confident in our ability to accelerate our positive trajectory. I’m honored to lead Integer as we execute our strategy of delivering innovative, cost-effective solutions to our Customers while generating profitable growth for our Company.”

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.